Fermer le menu


Member of Lyonbiopole


Development and manufacturing of ATMP / Novel Therapies for Animal Health

Vetbiobank, a French veterinary regenerative medicine company, develops since 2011 cost-effective animal stem cell drugs for treating multiple chronic inflammatory diseases and promoting animal well-being.

Vetbiobank, having a unique industrial know-how in veterinary cell therapy, has developed a proprietary GMP certified platform for manufacturing large volume and cost-effective animal neonatal cell-based drugs.

Our value proposition to vets and pet owners is a once-off administration of our neonatal canine Mesenchymal Stem Cells (MSCs), which fully respect animal welfare and is an alternative to NSAID.

Vetbiobank canine neonatal MSCs show long term efficacy, high safety profile and no observance issue. Convenient and economic (cost / time), they restore well-being over several months and postpone the potential need for surgery (eg. dysplasia)


Strategic application domain: Veterinary Medicine

Application market: Bioproduction, Immune, AutoIm & Inflam. diseases, Veterinary medicine

Type of activity: CMO - Production - Bioproduction, CRO - Tools - R&D platform, Therapeutics, Pharma or Biotech

Technologies: Animal model & In vivo testing, Cell Therapy - Stem cells - Cell Biology - Biobanking, Regenerative medicine

Created on sept. 28th, 2011 - 8 employees



Campus Vétérinaire - 1 Avenue Bourgelat 69280 Marcy l'Etoile



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.